Cipla Ltd., through its UK unit, Cipla EU, inked agreements to acquire the U.S.-based generics company, Invagen Pharmaceuticals Inc., and consulting firm Exelan Pharmaceuticals Inc., in an all-cash deal valued at $550 million.